Buchumschlag

Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial : methodology and mechanisms corner

Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-bl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kosiborod, Mikhail N. (Verfasst von) , Platz, Elke (Verfasst von) , Wharton, Sean (Verfasst von) , le Roux, Carel W. (Verfasst von) , Brückmann, Martina (Verfasst von) , Ajaz Hussain, Samina (Verfasst von) , Unseld, Anna (Verfasst von) , Startseva, Elena (Verfasst von) , Kaplan, Lee M. (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2024
In: JACC Heart failure
Year: 2024, Jahrgang: 12, Heft: 12, Pages: 2101-2109
ISSN:2213-1787
DOI:10.1016/j.jchf.2024.09.004
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jchf.2024.09.004
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2213177924006620
Volltext
Verfasserangaben:Mikhail N. Kosiborod, MD, Elke Platz, MD, MS, Sean Wharton, MD, Carel W. le Roux, MD, P HD, Martina Brueckmann, MD, Samina Ajaz Hussain, MD, MFPM, Anna Unseld, MS C, Elena Startseva, MD, MBA, Lee M. Kaplan, MD, PH D, the SYNCHRONIZE–CVOT Trial Committees and Investigators
Beschreibung
Zusammenfassung:Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body mass index ≥27 kg/m2 and established CV disease or chronic kidney disease, and/or at least 2 weight-related complications or risk factors for CV disease. The primary endpoint of SYNCHRONIZE-CVOT is time to first occurrence of the composite adjudicated endpoint of 5-point major adverse CV events. This global CV outcomes trial is currently enrolling, with a target recruitment of 4,935 participants. SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk. (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE-CVOT]; NCT06077864)
Beschreibung:Online verfügbar: 23. Oktober 2024, Artikelversion: 2. Dezember 2024
Gesehen am 10.04.2025
Beschreibung:Online Resource
ISSN:2213-1787
DOI:10.1016/j.jchf.2024.09.004

Ähnliche Einträge